Since November 2004, Charley’s Fund has directed $18 million into medical research to expedite the development of treatments for Duchenne muscular dystrophy. Initially our focus was translational research – research that moves the science from the laboratory into human clinical trials. We are pleased to report that we are now also funding clinical research. This is a clear indication that hopeful therapies are moving through the drug development pipeline. Through innovative partnerships with biotechnology companies and clinicians, we are having a clear and measurable impact on the speed of drug development for Duchenne muscular dystrophy. For further details, please click on each therapeutic strategy.